Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial

Kirsten C Morley1, Henry R Kranzler1, Natasha Luquin1

  • 1Specialty of Addiction Medicine, Sydney Medical School (Morley, Adams, Montebello, Tremonti, Dali, Logge, Haber), School of Health Sciences (Baillie), and Matilda Centre for Mental Health and Substance Use (Teesson), Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Edith Collins Centre for Translational Research in Alcohol, Drugs, and Toxicology (Morley, Jamshidi, Logge, Haber) and Department of Medical Genomics (Luquin, Trent), Royal Prince Alfred Hospital, Camperdown, Australia; Center for Studies of Addiction, Perelman School of Medicine, University of Pennsylvania, and Mental Illness Research, Education, and Clinical Center, Crescenz VA Medical Center, Philadelphia (Kranzler); Northern Sydney Local Health District Drug and Alcohol Services, St Leonards, Australia (Montebello); St Vincent's Hospital Sydney, Sydney, Australia (Tremonti).

Summary

Topiramate shows comparable effectiveness and safety to naltrexone for alcohol use disorder (AUD), with superior results in reducing craving and BMI. Genetic polymorphisms did not impact treatment response in this study.